Business
Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”
License of the MIT patent strengthens Rafael’s intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment of ApoE4-positive Alzheimer’s DiseaseNEWARK, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today announced that its subsidiary, Cyclo Therapeutics, has entered into an exclusive licensing agreement with Massachusetts Institute of Technology (“MIT”) covering U.S. Patent No.12285440. This license covers the use of cyclo
About this update from Rafael Holdings, Inc.
[{"type":"image","alt":"Rafael Holdings, Inc.","displaySize":"","headline":null,"caption":"Rafael Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":179,"height":61,"url":"https://media.zenfs.com/en/globenewswire.com/135483f9ca0ce750d79c23f2fecb7eff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1i2Oe.Du7.sdgVeiMLlvBA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTcy/https://media.zenfs.com/en/globenewswire.com/135483f9ca0ce750d79c23f2fecb7eff","width":179,"height":61}},"lazy":false},{"type":"text","content":"License of the MIT patent strengthens Rafael’s intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment of ApoE4-positive Alzheimer’s Disease","length":189,"tagName":"p"},{"type":"text","content":"NEWARK, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today announced that its subsidiary, Cyclo Therapeutics, has entered into an exclusive licensing agreement with Massachusetts Institute of Technology (“MIT”) covering U.S. Patent No.12285440. This license covers the use of cyclodextrins in patients with Alzheimer's Disease (AD) who carry an ApoE4 genetic mutation, strengthening the company’s intellectual property portfolio around Trappsol® Cyclo™ in this important AD patient population.","length":527,"tagName":"p"},{"type":"text","content":"The ApoE4 gene variant is estimated to be present in 50-70% of patients with AD and is believed to be a key risk factor in the development early onset sporadic AD. Dysregulated cholesterol metabolism is believed to contribute to amyloid and tau pathology, especially in those patients with the ApoE4 gene variant, which has been shown to accelerate AD as it is the key lipids/cholesterol transporter in the brain.","length":413,"tagName":"p"},{"type":"text","content":"The established mechanism of action (MOA) for Trappsol® Cyclo™ could have a direct impact in ApoE4 positive patients as it has been shown to improve cholesterol transport between central nervous system (CNS) cells. Preclinical data suggest Trappsol® Cyclo™ can improve delivery of cholesterol between CNS cells, reduce tau-pathology and improve learning/memory in mice.","length":369,"tagName":"p"},{"type":"text","content":"“Securing this exclusive license from MIT represents a transformative milestone for our company and greater potential positive n...